Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlobalBio, Inc.
Cambridge, Massachusetts, United Statesglobalbioinc.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GlobalBio has developed a panel of anti-PD‑1 antibodies with diverse binding/functional profiles. Two candidates are entering preclinical development as immune checkpoint inhibitors for cancer therapy. The company leverages proprietary semisynthetic libraries and advanced computational methods to engineer improved therapeutic antibodies.
- Therapeutic areas
- OncologyOther
- Modalities
- Monoclonal antibodies (mAbs)Antibody-based therapiesRecombinant proteins
- Industry
- Biotech
02
Partnerships
Antiverse Ltd. – collaboration on AI-driven antibody discovery targeting immune checkpoints in cancer therapy.
Beyond the preview
Go deeper on GlobalBio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlobalBio, Inc..